Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
2,491,870
result(s) for
"Adult."
Sort by:
Correction: Prevalence and risk factors of the most common multimorbidity among Canadian adults
[This corrects the article DOI: 10.1371/journal.pone.0317688.].
Journal Article
Redefining post-traditional learning : emerging research and opportunities
\"\"This book explores changing student demographics and offers recommendations to current teaching methodologies through the lens of andragogy\"--Provided by publisher\"-- Provided by publisher.
Book
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease
ObjectivesAdult-onset Still’s disease (AOSD) is a rare systemic autoinflammatory disease; its management is largely empirical. This is the first clinical study to determine if interleukin (IL)-18 inhibition, using the recombinant human IL-18 binding protein, tadekinig alfa, is a therapeutic option in AOSD.MethodsIn this phase II, open-label study, patients were ≥18 years with active AOSD plus fever or C reactive protein (CRP) levels ≥10 mg/L despite treatment with prednisone and/or conventional synthetic disease-modifying antirheumatic drugs (DMARDs). Previous biological DMARD treatment was permitted. Patients received tadekinig alfa 80 mg or 160 mg subcutaneously three times per week for 12 weeks; those receiving 80 mg not achieving early predicted response criteria (reduction of ≥50% CRP values from baseline and fever resolution) were up-titrated to 160 mg for a further 12 weeks. The primary endpoint was the occurrence of adverse events (AEs) throughout the study.ResultsTen patients were assigned to receive 80 mg tadekinig alfa and 13 patients to the 160 mg dose. One hundred and fifty-five treatment-emerging AEs were recorded, and 47 were considered related to the study drug. Most AEs were mild and resolved after drug discontinuation. Three serious AEs occurred, one possibly related to treatment (toxic optic neuropathy). At week 3, 5 of 10 patients receiving 80 mg and 6 of 12 patients receiving 160 mg achieved the predefined response criteria.ConclusionsOur results indicate that tadekinig alfa appears to have a favourable safety profile and is associated with early signs of efficacy in patients with AOSD.Trial registration numberNCT02398435.
Journal Article
The persons in relation perspective : in counselling, psychotherapy and community adult learning
People are constituted by their relationships, past and present, inner and outer, conscious and unconscious. People are agents who experience, know and act on the world. At the heart of your agency is your self: positive, puzzling, and problematic. Colin Kirkwood explores these and other ideas of John Macmurray, Ian Suttie, Ronald Fairbairn, John D Sutherland and Paulo Freire, and shows how they apply in counselling and psychotherapy, adult education, community and society. In today's world, a set of ideas, attitudes and practices has taken hold, which emphasise the individual, self-centredness, pleasure-seeking, consumption, success and the accumulation of wealth and power. They are deeply harmful and need to be tackled. Colin demonstrates how these ideas affect us, and how they can be taken on and defeated, in a dialogical narrative of psychotherapy with a girl suffering from severe anorexia, written by the girl herself, her psychotherapist and one of her doctors.
Book
Correction: Development and validation of the Continuous Traumatic Stress Response scale (CTSR) among adults exposed to ongoing security threats
[This corrects the article DOI: 10.1371/journal.pone.0251724.].[This corrects the article DOI: 10.1371/journal.pone.0251724.].
Journal Article
Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study
[This corrects the article DOI: 10.1371/journal.pone.0245827.].
Journal Article